Scinai Immunotherapeutics (SCNI) Long-Term Deferred Tax (2021 - 2025)

Scinai Immunotherapeutics has reported Long-Term Deferred Tax for 5 years, with the latest figure at $28.1 million in Q4 2025.

• Quarterly Long-Term Deferred Tax rose 20.18% year-over-year to $28.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $28.1 million (up 20.18% YoY) and the FY2025 annual result came in at $28.1 million, up 20.18% from the prior year.
• Long-Term Deferred Tax climbed to $28.1 million in Q4 2025 per SCNI's latest filing, from $23.4 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $28.1 million in Q4 2025 and troughed at $19.6 million in Q4 2021.
• A 5-year average of $23.9 million and a median of $23.4 million in 2024 frame the typical range for Long-Term Deferred Tax.
• The sharpest annual moves came in 2024 and 2025: Long-Term Deferred Tax declined 10.63% in 2024, then climbed 20.18% in 2025.
• Over 5 years, Long-Term Deferred Tax stood at $19.6 million in 2021, then gained by 12.52% to $22.0 million in 2022, then advanced by 18.97% to $26.2 million in 2023, then fell by 10.63% to $23.4 million in 2024, then increased by 20.18% to $28.1 million in 2025.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $28.1 million, $23.4 million, and $26.2 million for Q4 2025, Q4 2024, and Q4 2023 respectively.